Vallance P, Leone A, Calver A, Collier J, Moncada S.Accumulation of an endogenous inhibitor of NO synthesis in chronic renal failure. Lancet1992; 339: 572-575.
2.
Miyazaki H, Matsuoka H, Cooke JP.Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation1999; 99: 1141-1146.
3.
Zoccali C, Bode-Böger SM, Mallamaci Fet al.Asymmetric dimethylarginine (ADMA): an endogenous inhibitor of nitric oxide synthase predicts mortality in end-stage renal disease (ESRD). Lancet2001; 358: 2113-2117.
4.
Valkonen VP, Päivä H, Salonen JTet al.Risk of acute coronary events and serum concentration of asymmetrical dimethylargi-nine. Lancet2001; 358: 2127-2128.
5.
Dayoub H, Achan V, Adimoolam Set al.Dimethylarginine dimethylaminohydrolase regulates nitric oxide synthesis: genetic and physiological evidence. Circulation2003; 108: 3042-3047.
6.
Böger RH.The emerging role of ADMA as a novel cardiovascular risk factor. Cardiovasc Res2003; 59: 824-833.
7.
Cooke JP.Asymmetrical dimethylarginine: the Über marker?Circulation2004; 109: 1813-1818.
8.
Vallance P, Leiper J.Cardiovascular biology of the asymmetric dimethylarginine: dimethylarginine dimethylaminohydrolase pathway. Arterioscler Thromb Vasc Biol2004; 24: 1023-1030.
